Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT3 | Q9Y243 | 18/20 | 0.47 |
| ▸ | IKBKB | O14920 | 1/20 | 0.42 |
| ▸ | ABL1 | P00519 | 1/20 | 0.41 |
| ▸ | BCR | P11274 | 1/20 | 0.41 |
| ▸ | SRC | P12931 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12423285 | 0.91 | AKT3 (0.48) | AKT3IKBKB | |
| SCHEMBL12423244 | 0.90 | AKT3 (0.50) | AKT3IKBKB | |
| SCHEMBL12423272 | 0.88 | AKT3 (0.46) | AKT3IKBKBABL1SRC | |
| SCHEMBL12423308 | 0.88 | AKT3 (0.54) | AKT3IKBKB | |
| SCHEMBL12423256 | 0.87 | AKT3 (0.52) | AKT3IKBKB | |
| SCHEMBL12423311 | 0.87 | ROCK1 (0.47) | AKT3IKBKB | |
| SCHEMBL12423250 | 0.86 | AKT3 (0.67) | AKT3IKBKB | |
| SCHEMBL13154135 | 0.86 | AKT3 (0.54) | AKT3 | |
| SCHEMBL13154120 | 0.86 | AKT3 (0.50) | AKT3IKBKB | |
| SCHEMBL12423295 | 0.86 | AKT3 (0.55) | AKT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7977481-B2 | Pyrimidinyl-thiophene kinase modulators | SGX PHARMACEUTICALS, INC. (US) | 2011-07-12 | — | — | US | disclosed |
| US-20100305128-A1 | Pyrimidinyl-Thiophene Kinase Modulators | ARNOLD WILLIAM D | 2010-12-02 | — | — | US | disclosed |
| US-7803806-B2 | Pyrimidinyl-thiophene kinase modulators | SGX PHARMACEUTICALS, INC. (US) | 2010-09-28 | — | — | US | disclosed |
| EP-1948647-A1 | PYRIMIDINYL-THIOPHENE KINASE MODULATORS | SGX Pharmaceuticals, Inc. (US) | 2008-07-30 | — | — | EP | disclosed |
| US-20070117800-A1 | PYRIMIDINYL-THIOPHENE KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2007-05-24 | — | — | US | disclosed |
| WO-2007053776-A1 | PYRIMIDINYL-THIOPHENE KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2007-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305128-A1 | Pyrimidinyl-Thiophene Kinase Modulators | MAP3K20, MAP3K6, MAP4K2 | AKT3 340/4885IKBKB 553/4885ABL1 45/4885 |
| US-20070117800-A1 | PYRIMIDINYL-THIOPHENE KINASE MODULATORS | MAP3K20, MAP3K6, MAP4K2 | AKT3 340/4885IKBKB 553/4885ABL1 45/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.